Articles From: Gildan Activewear Will Hold its Fiscal 2014 Fourth Quarter and Full Year Results Conference Call at 8:30 AM ET on December 4, 2014 to Glacier Bancorp, Inc. Declares Quarterly Dividend


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0980158001&sourceType=1 http://www.ccnmatthews.com/logos/20110803-gildan_200_2.jpg MONTREAL, QUEBEC --
Sign-up for Gildan Activewear Will Hold its Fiscal 2014 Fourth Quarter and Full Year Results Conference Call at 8:30 AM ET on December 4, 2014 investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer.
Sign-up for Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni ® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals.
Sign-up for Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi ® by the U.S. Food and Drug Administration in December 2013, and the investigational NS5A inhibitor GS-5816 for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig ® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL). The findings are being presented this week at the Annual Meeting of the American Society of Hematology (ASH). Zydelig is indicated in the United States as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies, and in combination with rituximab for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy due to comorbidities.
Sign-up for Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches: The senior notes are rated A- by Standard & Poor's and A3 by Moody's.
Sign-up for Gilead Prices $4 Billion of Senior Unsecured Notes investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended September 30, 2014.
Sign-up for Gilead Sciences Announces Third Quarter 2014 Financial Results investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2014 financial results will be released on Tuesday, October 28, at 4:05 p.m. Eastern Time.
Sign-up for Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 investment picks
Gilead Sciences' stock (GILD) slumped 3.5% in after-hours trade Tuesday, after the biotechnology company reported third-quarter profit that missed expectations.
Sign-up for Gilead Sciences' stock pulls back from record high close after earnings miss investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection in adults.
Sign-up for Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV investment picks
2014/10/10
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch)--Gilead Sciences Inc. on Friday won regulatory approval for a follow-on medication to its controversial hepatitis C drug Sovaldi, and this new treatment surpasses its predecessor's $1,000-a-day price tag.
Sign-up for Gilead's new drug is even pricier than Sovaldi investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives.
Sign-up for Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Gilman Louie Joins Cubic Executive Advisory Board investment picks
2014/11/11
American Automobile Association, Max Muscle, Wingstop and Sport Clips coming soon! OAK BROOK, Ill.
Sign-up for Gilroy Continues Revitalization as Pacheco Pass Signs over 9,000 Square Feet in New Leases investment picks
2014/9/18
Be Safe and Replace Smoke Alarms with New High-tech, High-style Options AURORA, Ill.
Sign-up for Gimme Five! Safety In Numbers investment picks
Intuit Inc. (NASDAQ:INTU) has called journalist, television personality and entrepreneur Giuliana Rancic to the main stage to speak at QuickBooks Connect , taking place on Wednesday, October, 22 nd in San Jose, Calif.
Sign-up for Giuliana Rancic Joins QuickBooks Connect Main Stage Lineup investment picks
2014/11/12
Give the gift of financial cheer by teaching kids the ABCs of good money management Canada NewsWire TORONTO , Nov.
Sign-up for Give the gift of financial cheer by teaching kids the ABCs of good money management investment picks
2014/11/25
Why wait in long lines this holiday season when you can give the PECO Smart Gift of Energy instead?
Sign-up for Give the Gift of Warmth this Holiday Season with the PECO Smart Gift of Energy investment picks
2014/11/17
Find out where you can recycle in your area MILWAUKEE , Nov.
Sign-up for Give your car battery another life investment picks
2014/11/24
- Review of offers within RetailMeNot's database of deals from 2013 shows Thanksgiving and Black Friday promotions both had an average discount of 37% off - It's not just Black Friday that draws the early birds; 80% of respondents said they would wake up early Thanksgiving Day to shop for a deal - Over 1 in 5 (21%) Black Friday shoppers report that they have never missed a year of shopping for deals on Black Friday AUSTIN, Texas , Nov.
Sign-up for Giving Thanks for Good Deals: Despite Backlash, Thanksgiving Day Becomes a Preferred Shopping Holiday, With Black Friday Holding Strong investment picks
ADVISORY, Oct.
Sign-up for GLAAD to Ring The Nasdaq Stock Market Opening Bell investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971592001&sourceType=1 http://www.ccnmatthews.com/logos/20081113-gvc.gif VANCOUVER, BRITISH COLUMBIA --
Sign-up for Glacier Acquires Majority Interest in Evaluate Energy investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0979041001&sourceType=1 http://www.ccnmatthews.com/logos/20081113-gvc.gif VANCOUVER, BRITISH COLUMBIA --
Sign-up for Glacier Announces Quarterly Dividend investment picks
KALISPELL, Mont., Nov.
Sign-up for Glacier Bancorp, Inc. Announces Acquisition of Community Bank, Inc. in Ronan, Montana investment picks
2014/10/23
HIGHLIGHTS: All time record net income of $29.3 million for the current quarter, an increase of 2 percent from the prior quarter net income of $28.7 million and an increase of 14 percent from the prior year third quarter net income of $25.6 million.
Sign-up for Glacier Bancorp, Inc. Announces Results for the Quarter Ended September 30, 2014 investment picks
KALISPELL, Mont., Oct.
Sign-up for Glacier Bancorp, Inc. Announces Succession Planning Process for President and CEO investment picks
KALISPELL, Mont., Oct.
Sign-up for Glacier Bancorp, Inc. Announces Third Quarter Earnings Release and Conference Call investment picks
KALISPELL, Mont., Sept.
Sign-up for Glacier Bancorp, Inc. Declares Quarterly Dividend investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Gildan Activewear Will Hold its Fiscal 2014 Fourth Quarter and Full Year Results Conference Call at 8:30 AM ET on December 4, 2014 to Glacier Bancorp, Inc. Declares Quarterly Dividend
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent